A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile

Hanna Czajka, Volker Schuster, Fred Zepp, Susanna Esposito, Martine Douha, Paul Willems

Research output: Contribution to journalArticle

Abstract

Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

Original languageEnglish
Pages (from-to)6504-6511
Number of pages8
JournalVaccine
Volume27
Issue number47
DOIs
Publication statusPublished - Nov 5 2009

Keywords

  • Combined MMRV vaccine
  • Immunogenicity
  • Reactogenicity

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Fingerprint Dive into the research topics of 'A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile'. Together they form a unique fingerprint.

  • Cite this